Unsal, VelidUnsal, VelidIlhan Sabancilar, Fidel Demir, Gulten Toprak, Zafer Pekkolay2023-07-262023-07-262023https://pubmed.ncbi.nlm.nih.gov/36855973/#full-view-affiliation-1https://hdl.handle.net/20.500.12514/3536https://www.scopus.com/record/display.uri?eid=2-s2.0-85149153498&origin=SingleRecordEmailAlert&dgcid=raven_sc_affil_en_us_email&txGid=867a81c1e8179f50eea0e261c6af3e7aIntroduction: Sclerostin is a glycoprotein known as a negative regulator of bone formation, predominantly expressed by mature osteocytes. There is no causative evidence information on the role of sclerostin in the pathogenesis of type 2 diabetes mellitus (T2DM) in humans. Aim: This study aimed to investigate the relationship between serum sclerostin levels and oxidative status and biochemical parameters in T2DM patients and healthy people. Materials and methods: This cross-sectional study, conducted in a clinical trial center, included 45 subjects with T2DM and 45 subjects as controls. Results: Serum sclerostin, total oxidative status (TOS), albumin, and ferritin levels were significantly higher in T2DM patients than in the control group (p<0.05). Total antioxidant status (TAS) was significantly higher in the control group (p<0.05). There was a weak positive correlation between sclerostin and TOS (r=0.23, p=0.03) and a weak negative correlation between sclerostin and TAS (r=-0.28, p=0.03). Conclusions: We have demonstrated that serum sclerostin levels increase in patients with T2DM and that the increased sclerostin levels are associated with oxidative stress.en10.3897/folmed.65.e72953info:eu-repo/semantics/openAccessTAS; TOS; sclerostin; type 2 diabetes mellitusArticle65146522-s2.0-8514915349836855973